Megestrol Oncoeurope (Megestrol Acetate)

Megestrol acetate binds to progesterone receptors, producing antineoplastic effects in hormone‑sensitive tumors. It also exerts glucocorticoid‑like activity that influences hypothalamic pathways, reduces catabolic cytokines, and enhances appetite, leading to weight gain in patients with severe wasting.

The appropriate dose of Megestrol Oncoeurope is individualized by the prescribing clinician based on the patient’s condition, severity of cachexia, cancer type, and overall health status. No fixed regimen is provided here; the prescriber sets the dose and schedule.

Safety data for Megestrol acetate in pregnancy are limited, and the drug is generally avoided unless the potential benefit justifies the risk. It is also not recommended during breastfeeding because it may pass into milk and affect the infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Megestrol Oncoeurope. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Megestrol acetate is a progestin with both appetite‑stimulating and antineoplastic properties, distinguishing it from agents such as mirtazapine or dronabinol, which primarily act on central neurotransmitters. Its dual hormonal activity makes it especially useful in cancer‑related cachexia where tumor control is also a goal.

Megestrol Oncoeurope should be stored at ambient temperature below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Megestrol Oncoeurope is taken orally, typically as a tablet swallowed with water. The exact dosing schedule and whether it is taken with food are determined by the prescribing clinician based on the individual treatment plan.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal suppression leading to cortisol deficiency, severe hyperglycemia, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of these conditions.

Megestrol Oncoeurope should be avoided in patients with known hypersensitivity to meg​estrol acetate, active uncontrolled thromboembolic disease, severe uncontrolled diabetes, or in those where pregnancy benefits outweigh potential risks. Clinicians must evaluate each patient’s medical history before prescribing.